Drug intelligence / Profile preview

百妥平

Development stage: Unknown
Lead developer: 北京百奥药业
Modality: Small Molecules
Administration: Oral

Overview

**百妥平** is an approved oral fixed-dose combination tablet developed by Beijing Baiao Pharmaceutical for the treatment of type 2 diabetes mellitus. The product contains **empagliflozin** and **metformin**, combining an SGLT2 inhibitor that reduces renal glucose reabsorption and increases urinary glucose excretion with a biguanide antihyperglycemic agent that decreases hepatic glucose production and improves insulin sensitivity. It is a small-molecule combination product marketed in tablet form for glycemic control in adults with type 2 diabetes mellitus.

Brand names: 百妥平
Other names: 二甲双胍恩格列净片二甲双胍恩格列净片(I)metformin + empagliflozinmetformin + empagliflozin tabletsBaituo Ping

Targets

SGLT2 (Sodium-glucose cotransporter protein subunit 2)

Beyond the preview

Go deeper on 百妥平.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 百妥平.

Explore the full profile